Background: Testicular germ cell tumor (TGCT) is the most common malignancy among young men. We conduct this study in order to further understand the genetic determinants of TGCT. Methods: Eighteen TGCTs and matched normal controls were obtained from individuals newly diagnosed with TGCT in the hospital. Genomic DNAs were extracted from these samples and whole-exome sequencing was conducted by Hiseq 2000 platform. Copy number variations were called by exomeCNV based on the BWA alignments. Potential somatic substitutions and preliminary list of somatic indels were detected by the analyzed from our data. And these detected mutations were validated by Sanger sequencing. Results: We identified a total of 77 nonsynonymous mutations with a uniformly low mutation rate of 0.14 mutations/Mb per tumor, on average. Notably, no somatic SNV was identified in 16.7% (3/18) of the tumors. Nevertheless, CTNNB1 and FZD10 were previously reported related to TGCT, potentially involved in the Wnt signaling pathway, contributing to the reprogram process during human embryonal carcinoma differentiation. Besides, KIAA1486 was the only recurrent gene identified in two tumors samples. With genetic evidence from United Kingdom, our study confirmed that gain of 12p (40/60; 66.7%) is the most frequent chromosomal aberration. Conclusions: Our study uncovered a uniformly low mutation rate of these tumors, consistent with previous studies, supporting the embryonical origins of TGCT. Besides, the chromosomal aberrations were invariable presence, and no somatic SNV was identified in 16.7% (3/18) of the tumors, suggesting that chromosomal aberrations held a more critical role in the tumorigenesis of TGCT.
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Objective: Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Early detection is the effective way to improve the prognosis of patients with RCC. In the development and progression of cancer accompanied by metabolic changes, so metabolomics has special advantages in diagnosis of RCC. The aim of this study is to find discriminating metabolites from RCC through a non-target metabolomics method. Methods: We extracted the serum samples of RCC patients and controls for HPLC-MS detection, and used quantitative analysis of multivariate statistical methods were employed to analyze the data. Results: In this study, we found that the metabolite in RCC significantly different from the controls, metabolic pathways including arachidonic acid and sphingolipid metabolism were found to be disturbed in RCC patients compared with controls. Conclusions: Metabolite concentration in cells of the system change is most likely to switch to immune response and energy balance. This study indicates that metabolomics may be a valuable tool for the discovery of novel cancer biomarkers in the future. Objective: To research the expression of CCAT2 in renal cell carcinoma (RCC), bladder cancer and paired normal tumor-adjacent tissues and investigate the correlations between expression of CCAT2 and clinicopathologic characteristics for further study of the role of CCAT2 in RCC and bladder cancer. Methods: Total RNA isolated from 40 RCC and 37 bladder cancer tissues and paired normal tumor-adjacent normal tissues which random selected from specimen bank was used for obtaining cDNA by performing reverse transcription. Using real-time PCR (RT-PCR) to detect the expression of CCAT2 in specimen, then using statistical method to analysis the relationships between the expression of CCAT2 and clinicopathologic characteristic. Results: The expression of CCAT2 in RCC tissues was significantly lower than in paired normal tumor-adjacent tissues (P<0.01), with 33 cases (82.5%) showing downregulation of CCAT2. While the expression of CCAT2 in bladder cancer tissues was significantly higher than in paired normal tumor-adjacent tissues (P<0.01),with 31 cases (83.8%) showing up-regulation of CCAT2.No relationships were found between the expression of CCAT2 and patients'
